Based on analyst estimates for Q3 2025, Pfizer was expected to report revenue around $16.4 billion and EPS of $0.60. The actual revenue of $16.654 billion slightly beat expectations, and the reported EPS of $0.62 also exceeded the estimate. Therefore, the sentiment is somewhat positive.
Analysis Details
AI-POWERED INSIGHTSAffected Securities
SourcePFIZER INC
PublishedNovember 4, 2025 at 12:03 PM Historical Context
AI Confidence70% Moderate
ImplicationPotential upside for related securities
Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Always consult with a qualified financial advisor before making investment decisions.